Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
Avi Kapoor 1 month ago
MarketsAnalyst RatingsPrice TargetEarnings
Danaher beat Q3 earnings and revenue estimates, raised FY2026 profit guidance, and analysts lifted price targets despite shares falling 1.8%.
Danaher Corp. (NYSE:DHR) on Wednesday reported upbeat earnings for the third quarter.
The company posted third-quarter adjusted earnings of $2.11 per share, beating the analyst consensus estimate of $1.92. Revenue rose 8.5% year over year to $6.6 billion, beating the analysts’ expectations of $6.559 billion.
Julie Sawyer Montgomery, President and CEO, stated, "We delivered better-than-expected third-quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets."
For the fourth quarter of 2026, Danaher anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0% range year-over-year.
The company expects respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%. Danaher raised its fiscal 2026 adjusted earnings forecast from $8.45-$8.60 per share to $8.57-$8.62 per share versus the consensus of $8.51.
Danaher shares fell 1.8% to trade at $229.85 on Thursday.
These analysts made changes to their price targets on Danaher following earnings announcement.
- Baird analyst Catherine Schulte maintained the stock with an Outperform rating and raised the price target from $246 to $254.
- Stifel analyst Daniel Arias maintained the stock with a Buy and raised the price target from $220 to $260.
- TD Cowen analyst Dan Brennan maintained the stock with a Buy and raised the price target from $255 to $270.
- JP Morgan analyst Casey Woodring maintained the stock with an Overweight rating and raised the price target from $250 to $270.
- Barclays analyst Luke Sergott maintained the stock with an Overweight rating and boosted the price target from $255 to $260.
Photo via Shutterstock
More on DHR
FDA & biotech Benzinga
Danaher Unveils Microsoft AI Partnership to Accelerate Scientific ExperimentsDanaher partners with Microsoft to build AI scientific instruments on Azure and Foundry, cutting lab experiment times by up to 83%.

Benzinga
Danaher Enters Strategic Partnership With Microsoft To Develop Smart Scientific Instruments And Interoperable Agentic Ecosystem To Connect TechnologiesThe partnership seeks to combine Danaher's scientific, workflow and instrumentation expertise with Microsoft's AI technologies, making experimental execution more streamlined and insights more…
